RA Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

RA Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$160M	Hold	23,555,648	–	–	1.39%	18
2026 Q1	$105M	Hold	23,555,648	–	–	1.12%	21
2025 Q4	$130M	Hold	23,555,648	–	–	1.33%	17
2025 Q3	$77M	Hold	23,555,648	–	–	0.95%	27
2025 Q2	$54.4M	Buy	23,555,648 +12,683,145	+117%	+$27.6M	0.92%	25
2025 Q1	$15.1M	Hold	10,872,503	–	–	0.25%	55
2024 Q4	$18.8M	Hold	10,872,503	–	–	0.25%	58
2024 Q3	$21.9M	Hold	10,872,503	–	–	0.25%	53
2024 Q2	$24.4M	Hold	10,872,503	–	–	0.32%	48
2024 Q1	$31.2M	Sell	10,872,503 -7,600,000	-41%	-$15.8M	0.4%	50
2023 Q4	$32.7M	Hold	18,472,503	–	–	0.51%	38
2023 Q3	$58.4M	Buy	+18,472,503	New	+$34.5M	1.15%	25

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

RA Capital Management's TSHA Position: Q2 2026 in Review

RA Capital Management held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 23,555,648 shares worth $160M. The position accounts for 1.39% of the portfolio, ranked #18.

RA Capital Management first reported a position in TSHA in Q3 2023 and has held it in 12 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

RA Capital Management held 23,555,648 shares of Taysha Gene Therapies worth $160M as of Q2 2026.
RA Capital Management left its Taysha Gene Therapies share count unchanged in Q2 2026.
Taysha Gene Therapies made up 1.39% of RA Capital Management's portfolio in Q2 2026, its #18 holding.
RA Capital Management first reported a position in Taysha Gene Therapies in Q3 2023 and has held it in 12 quarters since.
209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.